A Phase 1 interventional study of Zongertinib and Itraconazole in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate the effect of multiple doses of the strong CYP3A inhibitor and recommended P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of a single dose of zongertinib in plasma following oral administration.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Period 1: a single oral dose of 15 milligrams (mg) zongertinib, film-coated tablet, was administered once on Day 1 (Day 1, Period 1, Visit 2), as reference treatment R. Treatment Period 2: a single oral solution of 200 mg (10 mg/mL in a 20 milliliter (mL) solution) itraconazole was administered once daily over 14 days (\[total: 14 doses\], from Day -3 to Day 11, Period 2). On Day 1 (Day 1, Period 2, Visit 3), 4th day of itraconazole treatment, a single oral dose of 15 mg zongertinib was administered 1 hour (h) after itraconazole administration as test treatment T. The two administrations of zongertinib were separated by a washout interval of at least 14 days. Zongertinib and itraconazole were orally administered with 240 mL of water after an overnight fast of at least 10 h for zongertinib and 9 h for itraconazole.
Drug: Zongertinib · Drug: Itraconazole
Zongertinib
Also known as: BI 1810631, Hernexeos®
Itraconazole
Also known as: Sempera® Liquid
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of zongertinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.
Time frame: Within 3 hours (h) prior to, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 47, 71, 119, 167 h for both periods, and additionally at 191, 215, 239, 263, and 287 h for period 2, after zongertinib administration.
Maximum Measured Concentration of Zongertinib in Plasma (Cmax)
Maximum measured concentration of zongertinib in plasma (Cmax) is reported.
Time frame: Within 3 hours (h) prior to, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 47, 71, 119, 167 h for both periods, and additionally at 191, 215, 239, 263, and 287 h for period 2, after zongertinib administration.
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Area under the concentration-time curve of zongertinib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported.
Time frame: Within 3 hours (h) prior to, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 47, 71, 119, 167 h for both periods, and additionally at 191, 215, 239, 263, and 287 h for period 2, after zongertinib administration.
This was a non-randomised, open-label, two-treatment, two-period, fixed-sequence crossover trial in healthy men. There was one group of participants, each participant underwent the fixed sequence of Reference (R) followed by Test (T) treatment, with a washout period of ≥14 days between zongertinib (BI 1810631) administrations.
| Milestone | Zongertinib Alone (R) / Zongertinib + Itraconazole (T) |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | Zongertinib Alone (R) / Zongertinib + Itraconazole (T) |
|---|---|
| Started | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Area under the concentration-time curve of zongertinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.
| Nanomoles * hour per Liter | Zongertinib Alone | Zongertinib + Itraconazole |
|---|---|---|
| Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 3014 ± NA | 4255 ± NA |
Maximum measured concentration of zongertinib in plasma (Cmax) is reported.
| Nanomoles per Liter | Zongertinib Alone | Zongertinib + Itraconazole |
|---|---|---|
| Maximum Measured Concentration of Zongertinib in Plasma (Cmax) | 138 ± NA | 175 ± NA |
Area under the concentration-time curve of zongertinib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported.
| Nanomoles * hour per Liter | Zongertinib Alone | Zongertinib + Itraconazole |
|---|---|---|
| Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 2892 ± NA | 4130 ± NA |
Collected over Zongertinib alone: From the first administration of zongertinib until first administration of itraconazole (IT), up to 14 days. IT alone: From the first administration of itraconazole until 2nd administration of zongertinib, up to 3 days. Zongertinib + IT: From the second administration of zongertinib until 8 days after the last administration of IT, up to 19 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zongertinib Alone | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Itraconazole Alone | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Zongertinib + Itraconazole | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Event | Zongertinib Alone | Itraconazole Alone | Zongertinib + Itraconazole |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/16 | 3/16 | 5/16 |
| HeadacheNervous system disorders | 3/16 | 0/16 | 1/16 |
| RashSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 2/16 |
| Abdominal painGastrointestinal disorders | 0/16 | 1/16 | 0/16 |
| FlatulenceGastrointestinal disorders | 0/16 | 1/16 | 0/16 |
| NauseaGastrointestinal disorders | 0/16 | 1/16 | 0/16 |
| AcneSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 1/16 |
| DiplopiaEye disorders | 0/16 | 0/16 | 1/16 |
| Hand fractureInjury, poisoning and procedural complications | 1/16 | 0/16 | 0/16 |
| SunburnInjury, poisoning and procedural complications | 0/16 | 0/16 | 1/16 |
Treated set (TS): The treated set included all participants who were treated with at least one dose of trial drug. The treated set was used for the safety analyses.
| Age, Continuous(Years) | Zongertinib Alone (R) / Zongertinib + Itraconazole (T) |
|---|---|
| Mean | 33.3 ± 8.6 |
| Sex: Female, Male(Participants) | Zongertinib Alone (R) / Zongertinib + Itraconazole (T) |
|---|---|
| Female | 0 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | Zongertinib Alone (R) / Zongertinib + Itraconazole (T) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Zongertinib Alone (R) / Zongertinib + Itraconazole (T) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Apr 2023 to primary completion in Jun 2023, 1 month.
Results were first posted in Sep 2025, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zongertinib